Table 3.
Characteristics of bilateral and unilateral patients with concordant and discordant confirmatory tests.
| Patient characteristics | Non-lateralized PA (n=63) | Lateralized PA (n=48) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Concordant | n | Discordant | P | n | Concordant | n | Discordant | P | |
| Before treatment | Before treatment | Before treatment | Before treatment | |||||||
| Sex [f/m] | 46 | 20/26 | 17 | 7/10 | 0.870 | 39 | 20/19 | 9 | 4/5 | 0.712 |
| Age | 46 | 52.7 ± 10.2 | 17 | 47.5 ± 11.2 | 0.152 | 39 | 49.2 ± 11.3 | 9 | 48.3 ± 12.4 | 0.959 |
| Duration of hypertension [months] | 46 | 120 ± 107 | 16 | 74 ± 80 | 0.122 | 39 | 88 ± 86 | 9 | 66 ± 78 | 0.419 |
| BMI [kg/m²] | 46 | 28.5 ± 4.8 | 17 | 28.5 ± 6.4 | 0.467 | 39 | 25.7 ± 3.4 | 9 | 26.6 ± 4.7 | 0.585 |
| SBP [mmHg] | 46 | 156 ± 17 | 17 | 163 ± 24 | 0.430 | 39 | 152 ± 15 | 9 | 155 ± 18 | 0.637 |
| DBP [mmHg] | 46 | 96 ± 13 | 17 | 104 ± 11 | 0.013 | 39 | 96 ± 9 | 9 | 99 ± 13 | 0.514 |
| Serum potassium [mmol/l] | 46 | 3.7 ± 0.3 | 17 | 3.8 ± 0.4 | 0.454 | 39 | 3.5 ± 0.5 | 9 | 3.6 ± 0.5 | 0.453 |
| PAC [pg/ml] | 46 | 171 ± 77 | 17 | 170 ± 144 | 0.249 | 39 | 227 ± 187 | 9 | 193 ± 99 | 0.937 |
| DRC [µU/ml] | 46 | 3.6 ± 2.7 | 17 | 4.7 ± 3.3 | 0.347 | 39 | 4.3 ± 4.2 | 9 | 2.8 ± 1.5 | 0.432 |
| ARR [pg/ml/μU/ml] | 46 | 60.9 ± 37.1 | 17 | 42.5 ± 28.3 | 0.037 | 39 | 77.4 ± 70.1 | 9 | 73.3 ± 41.7 | 0.606 |
| DDD [n] | 46 | 1.7 ± 1.3 | 17 | 1.7 ± 1.8 | 0.595 | 39 | 2.1 ± 2.7 | 9 | 2.0 ± 1.6 | 0.661 |
ARR, aldosterone-to-renin ratio; BMI, body mass index; DBP, diastolic blood pressure; DDD, defined daily doses of antihypertensive medications; DRC, direct renin concentration; PAC, plasma aldosterone concentration; SBP, systolic blood pressure.
Significance is marked bold.